Načítá se...
A Prospective, Open-Label, Observational, Postmarket Study Evaluating VYC-17.5L for the Correction of Moderate to Severe Nasolabial Folds Over 12 Months
BACKGROUND: VYC-17.5L (17.5 mg/mL hyaluronic acid, 0.3% lidocaine) is a dermal filler intended for deep dermis injection for the treatment of skin depressions. OBJECTIVE: To evaluate 12-month effectiveness and safety of VYC-17.5L for the treatment of moderate/severe nasolabial folds (NLFs). METHODS:...
Uloženo v:
Vydáno v: | Dermatol Surg |
---|---|
Hlavní autoři: | , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Lippincott Williams & Wilkins
2017
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5414733/ https://ncbi.nlm.nih.gov/pubmed/28165349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/DSS.0000000000000939 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|